BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

Merck & Co. Inc. (NYSE:MRK) hired Matthew Walsh as CFO and Rachel Stahler as chief information officer of its planned spinout Organon & Co. Walsh was EVP and CFO of Allergan plc, which was acquired...
BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

Dave Mott, the former Smith Barney investment banker, CEO of MedImmune and longtime VC, has announced his retirement from New Enterprise Associates. Mott, who has led the firm’s biopharma practice since 2008, plans to focus...
BC Extra | Dec 6, 2019
Financial News

Financing Roundup: Immunomedics, Ardelyx, Millendo, Omeros, Athenex

Since market close on Wednesday, Immunomedics, Ardelyx, Millendo and Omeros raised a total of $450 million in follow-ons, while Athenex raised $60 million via a private placement. Immunomedics Inc. (NASDAQ:IMMU) raised $250 million on Wednesday,...
BC Extra | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said COO Wladimir Hogenhuis will step down on Jan. 10 due to personal reasons. Cellular metabolism-focused company Agios Pharmaceuticals Inc. (NASDAQ:AGIO) hired Jonathan Biller as chief legal officer,...
BC Extra | Nov 26, 2019
Company News

Nov. 26 Company Quick Takes: Kyowa, Ardelyx expand partnership; plus ICER, Celltrion, Asahi-Veloxis and Merck

Kyowa, Ardelyx expand collaboration with new targets and $20M investment  Under an expanded partnership, Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) will pay Ardelyx Inc. (NASDAQ:ARDX) $10 million in research support over the next two years...
BC Extra | Sep 13, 2019
Company News

Sept. 12 Company Quick Takes: Atomwise in China deal; plus Ardelyx, GSK, Amarin, deCode

Atomwise, Hansoh in AI drug discovery deal   AI-based drug discovery company Atomwise Inc. (San Francisco, Calif.) has partnered with Hansoh Pharmaceutical Group Co. Ltd. (Jiangsu, China) to design and develop drug candidates against up...
BC Extra | Sep 3, 2019
Clinical News

Ardelyx gains on Phase III hyperphosphatemia combination data

Ardelyx's tenapanor combination met all endpoints in the Phase III AMPLIFY trial for hyperphosphatemia, setting the stage for a planned 2020 NDA submission once it has long-term monotherapy safety data in hand. Ardelyx Inc. (NASDAQ:ARDX)...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Nov 28, 2018
Company News

Management tracks: Abeona, INKEF, Incyte

Abeona Therapeutics Inc. (NASDAQ:ABEO) terminated Carsten Thiel for personal misconduct towards colleagues, less than eight months after hiring him as CEO. The rare genetic disease company named Head of R&D and CMO João Siffert interim...
Items per page:
1 - 10 of 83
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

Merck & Co. Inc. (NYSE:MRK) hired Matthew Walsh as CFO and Rachel Stahler as chief information officer of its planned spinout Organon & Co. Walsh was EVP and CFO of Allergan plc, which was acquired...
BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

Dave Mott, the former Smith Barney investment banker, CEO of MedImmune and longtime VC, has announced his retirement from New Enterprise Associates. Mott, who has led the firm’s biopharma practice since 2008, plans to focus...
BC Extra | Dec 6, 2019
Financial News

Financing Roundup: Immunomedics, Ardelyx, Millendo, Omeros, Athenex

Since market close on Wednesday, Immunomedics, Ardelyx, Millendo and Omeros raised a total of $450 million in follow-ons, while Athenex raised $60 million via a private placement. Immunomedics Inc. (NASDAQ:IMMU) raised $250 million on Wednesday,...
BC Extra | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said COO Wladimir Hogenhuis will step down on Jan. 10 due to personal reasons. Cellular metabolism-focused company Agios Pharmaceuticals Inc. (NASDAQ:AGIO) hired Jonathan Biller as chief legal officer,...
BC Extra | Nov 26, 2019
Company News

Nov. 26 Company Quick Takes: Kyowa, Ardelyx expand partnership; plus ICER, Celltrion, Asahi-Veloxis and Merck

Kyowa, Ardelyx expand collaboration with new targets and $20M investment  Under an expanded partnership, Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) will pay Ardelyx Inc. (NASDAQ:ARDX) $10 million in research support over the next two years...
BC Extra | Sep 13, 2019
Company News

Sept. 12 Company Quick Takes: Atomwise in China deal; plus Ardelyx, GSK, Amarin, deCode

Atomwise, Hansoh in AI drug discovery deal   AI-based drug discovery company Atomwise Inc. (San Francisco, Calif.) has partnered with Hansoh Pharmaceutical Group Co. Ltd. (Jiangsu, China) to design and develop drug candidates against up...
BC Extra | Sep 3, 2019
Clinical News

Ardelyx gains on Phase III hyperphosphatemia combination data

Ardelyx's tenapanor combination met all endpoints in the Phase III AMPLIFY trial for hyperphosphatemia, setting the stage for a planned 2020 NDA submission once it has long-term monotherapy safety data in hand. Ardelyx Inc. (NASDAQ:ARDX)...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Nov 28, 2018
Company News

Management tracks: Abeona, INKEF, Incyte

Abeona Therapeutics Inc. (NASDAQ:ABEO) terminated Carsten Thiel for personal misconduct towards colleagues, less than eight months after hiring him as CEO. The rare genetic disease company named Head of R&D and CMO João Siffert interim...
Items per page:
1 - 10 of 83